Navigation Links
Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
Date:12/4/2008

MENLO PARK, Calif., Dec. 4 /PRNewswire/ -- Long-term data published in EuroIntervention showed that the expected decrease in Mitral Vale Area (MVA) after repair with the MitraClip(R) system to correct mitral regurgitation (MR) is not associated with clinically significant mitral stenosis. Additionally, with two years of follow-up, none of the patients treated with the MitraClip(R) system required surgery for mitral stenosis. At 12 months no important differences were reported between the use of one or two MitraClip(R) devices or based on the etiology of MR.

The analysis was conducted to assess diastolic mitral valve function after percutaneous repair. Echocardiographic measurements of MVA and mean trans- Mitral Valve Gradient (MVG) were made in 96 patients implanted with the MitraClip(R) device. Patients were followed for up to two years.

The MitraClip(R) system is the first commercially available medical device which provides a non-surgical mitral valve repair option for patients suffering from the effects of MR. The MitraClip(R) system is available commercially in Europe and is currently in late stage clinical trials in the United States.

MR affects millions of people worldwide and is the most common type of heart valve insufficiency in Europe and in the United States. The vast majority of patients with significant MR are untreated, which leaves their hearts affected by the chronic volume overload caused by MR, requiring the heart to work harder, and ultimately leading to heart failure.

"It is important to know that the encouraging results from use of the MitraClip(R) system were maintained at two years without mitral stenosis," said Howard C. Herrmann, M.D., director, Interventional Cardiology and Cardiac Catheterization Laboratories at the hospital of the University of Pennsylvania and lead author of the manuscript. "With these results, we have a growing body of evidenc
'/>"/>

SOURCE Evalve, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
4. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
5. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
(Date:7/28/2014)... 2014  Air Products (NYSE: APD ) ... is vital to any healthcare facility. This understanding has ... improve the efficiency of its oxygen supply systems, but ... systems—including systems for emergency oxygen supply and ... at the 51 st ASHE Annual Conference ...
(Date:7/28/2014)...  VigeneTech, Inc, in collaboration with BioLegend, Inc., ... Software, an OEM software solution for analysis of ... offers varieties of bead-based multi-analyte immunoassay products for ... VigeneTech,s data analysis software, FCS data files can ... LEGENDplex™ software is a robust ...
Breaking Medicine Technology:Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2
... Hypertension demonstrate that early blockade of angiotensin II reversed vascular ... ... June 16 A new study published in the,current Journal of ... was effective in reversing,the narrowing of the arteries that occurs in ...
... 90th Annual Meeting -, SAN FRANCISCO and ... BNVI ) today announced results from in vitro ... data were presented at the,Endocrine Society 90th Annual ... stem cells and expressing native estrogen,receptors, MF101, an ...
Cached Medicine Technology:New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 2New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 3New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 4New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 5New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 6New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 7New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 8New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 9Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation 2Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation 3
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types ... Agents, Bio-Fuel, Animal Feed), & Geography - Global ... the global industrial enzymes market with analysis and ... It also identifies driving and restraining factors for ... trends, opportunities, burning issues, winning imperatives, and challenges. ...
(Date:7/28/2014)... (Boston)-- Researchers from Boston University School of Medicine (BUSM) ... increase the risk of developing Alzheimer,s disease (AD). The ... new drug treatment options that target PLXNA4 specifically. These ... , AD is the most frequent age-related dementia affecting ... 65 and older, and more than 40 percent of ...
(Date:7/28/2014)... "Fist bumping" transmits significantly fewer bacteria than ... cultural expectation of hand-to-hand contact between patients and ... August issue of the American Journal of ... Association for Professionals in Infection Control and Epidemiology ... of Biological, Environmental, and Rural Sciences at Aberystwyth ...
(Date:7/28/2014)... 2014) -- Researchers from The University of Texas Health Science ... institutions have identified a combination of pills that cures 9 ... drugs sofosbuvir and simeprevir, with or without ribavirin, cured 93 ... by patients, according to the study published today in ... the U.S. , Eric Lawitz, M.D., clinical professor in ...
(Date:7/28/2014)... WA (PRWEB) July 28, 2014 ... consulting and care management organizations, has published a ... low-cost approach to engaging patients and families in ... environments at multiple hospitals, the toolkit provides a ... huddle” with patients and their families early in ...
Breaking Medicine News(10 mins):Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Researchers identify potential biomarker for AD 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2
... help college students retain and integrate new information to ... abstract that will be presented Tuesday, June 14, in ... of the Associated Professional Sleep Societies LLC (APSS). ... microeconomics test was preserved after a 12-hour period that ...
... Getting six to nine hours of sleep per night is ... ratings for depression, suggests a research abstract that will be ... the 25th Anniversary Meeting of the Associated Professional Sleep Societies ... sleep duration of six to nine hours per night had ...
... , MONDAY, June 13 (HealthDay News) -- Spending ... increased overall and especially among certain groups of patients, a ... aged 18 and older who used glaucoma medication between 2001 ... medications increased from $445 in 2001 to $557 in 2006. ...
... Ill. June 13, 2011 A new ... preparation are associated with relatively high adenoma (precancerous ... substantially decreases colonoscopy effectiveness and may mandate an ... context of suboptimal bowel preparation, of all adenomas ...
... National Institutes of Health researchers have identified a new pathway ... The study provides insights about the interaction between a toxic ... chromosomes like aglets, the plastic tips that bind the ends ... National Human Genome Research Institute (NHGRI) appears in the June ...
... China? Boys are considered a greater asset for farming, but ... want a boy at any cost doubled? Sociologist ... families in China choose to abort girls. When ... born in China, a nationwide campaign was started against sex-selective ...
Cached Medicine News:Health News:Sleep can boost classroom performance of college students 2Health News:The good life: Good sleepers have better quality of life and less depression 2Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 2Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 3Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 4Health News:NIH researchers find new clues about aging 2Health News:NIH researchers find new clues about aging 3Health News:NIH researchers find new clues about aging 4Health News:Has China's campaign against female feticide done more harm than good? 2
... is a threaded titanium anchor, ... procedures. The anchor features wide ... to optimize bone purchase, as ... to prevent suture binding. Fastin ...
... 5mm Super Revo Suture Anchor offers a ... a mini-open rotator cuff repair. The cutting ... is pre-threaded with two #2 strands of ... suture management are avoided with the Independent ...
... 5mm Super Revo Suture Anchor offers a ... a mini-open rotator cuff repair. The cutting ... is pre-threaded with two #2 strands of ... suture management are avoided with the Independent ...
The Linvatec UltraFix Suture Anchor System's smooth surface until deployed eliminates tissue, bone and suture damage and its ultra smooth eyelet hole preserves suture integrity....
Medicine Products: